PMID- 30988962
OWN - NLM
STAT- MEDLINE
DCOM- 20190624
LR  - 20220408
IS  - 2075-0528 (Electronic)
IS  - 2075-051X (Print)
IS  - 2075-051X (Linking)
VI  - 18
IP  - 4
DP  - 2018 Nov
TI  - Hypoglycaemia Among Insulin-Treated Patients with Diabetes: Evaluation of the 
      United Arab Emirates cohort of the International Operations-Hypoglycaemia 
      Assessment Tool study.
PG  - e447-e454
LID - 10.18295/squmj.2018.18.04.004 [doi]
AB  - OBJECTIVES: This study aimed to evaluate the incidence of hypoglycaemia among 
      insulin-treated patients with type 1 diabetes mellitus (T1DM) or type 2 diabetes 
      mellitus (T2DM) from the United Arab Emirates (UAE) cohort of the 
      non-interventional International Operations-Hypoglycaemia Assessment Tool study. 
      METHODS: This cross-sectional observational study took place at 25 patient care 
      centres in the UAE from October 2014 to May 2015. All adult patients with T1DM or 
      T2DM who had been treated with insulin for >12 months were included. 
      Self-assessment questionnaires and patient diaries were used to determine the 
      incidence of documented hypoglycaemia both prospectively (four weeks after 
      baseline) and retrospectively (six months and four weeks before baseline for 
      severe and non-severe hypoglycaemic events, respectively). RESULTS: A total of 
      325 patients were enrolled in the study, of which 82 (25.2%) had T1DM and 243 
      (74.8%) had T2DM. Among patients with T1DM, 71.4% reported hypoglycaemic events 
      retrospectively, with an incidence rate (IR) of 102.8 events per patient-year 
      (PY), while 95% reported hypoglycaemic events prospectively, with an IR of 63.1 
      events per PY. Additionally, 56.3% of patients with T2DM reported hypoglycaemic 
      events retrospectively, with an IR of 42.2 events per PY, while 91.9% reported 
      hypoglycaemic events prospectively, with an IR of 33.3 events per PY. CONCLUSION: 
      The prevalence and incidence of hypoglycaemia were high among insulin-treated 
      patients with T1DM and T2DM in the UAE. Individualised glycaemic goals, patient 
      education and blood glucose monitoring may help to reduce the incidence of 
      hypoglycaemia in this population.
FAU - Abusnana, Salah
AU  - Abusnana S
AD  - Department of Diabetes & Endocrinology, University Hospital Sharjah, United Arab 
      Emirates.
FAU - Beshyah, Salem A
AU  - Beshyah SA
AD  - Department of Medicine, Sheikh Khalifa Medical City, Abu Dhabi, United Arab 
      Emirates.
AD  - Department of Medicine, Dubai Medical College, Dubai, United Arab Emirates.
FAU - Al-Mutawa, Nawal
AU  - Al-Mutawa N
AD  - Department of Diabetes & Endocrinology, Al Qassimi Hospital, Sharjah, United Arab 
      Emirates.
FAU - Tahhan, Rima
AU  - Tahhan R
AD  - Department of Internal Medicine, Al Zahraa Hospital, Dubai, United Arab Emirates.
FAU - Jallo, Mahir
AU  - Jallo M
AD  - Department of Clinical Sciences, College of Medicine, Gulf Medical University, 
      Ajman, United Arab Emirates.
FAU - Arora, Ravi
AU  - Arora R
AD  - Department of Internal Medicine, NMC Specialty Hospital, Abu Dhabi, United Arab 
      Emirates.
FAU - Aly, Hazem
AU  - Aly H
AD  - Novo Nordisk Pharmaceutical Company, Dubai, United Arab Emirates.
FAU - Singhal, Sagar
AU  - Singhal S
AD  - Novo Nordisk Pharmaceutical Company, Dubai, United Arab Emirates.
LA  - eng
PT  - Journal Article
DEP - 20190328
PL  - Oman
TA  - Sultan Qaboos Univ Med J
JT  - Sultan Qaboos University medical journal
JID - 101519915
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Blood Glucose/analysis
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 1/drug therapy
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Female
MH  - Humans
MH  - Hypoglycemia/*drug therapy/epidemiology
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Self Report
MH  - Surveys and Questionnaires
MH  - United Arab Emirates
PMC - PMC6443274
OTO - NOTNLM
OT  - Hypoglycemia
OT  - Insulin
OT  - Type 1 Diabetes Mellitus
OT  - Type 2 Diabetes Mellitus
OT  - United Arab Emirates
COIS- CONFLICT OF INTEREST Professor Salah Abusnana and Dr Salem A. Beshyah received 
      research grants and financial support for the submitted work from Novo Nordisk 
      A/S Pharmaceutical Company. Professor Salah Abusnana, Dr Salem A. Beshyah, Dr 
      Mahir Jallo, Dr Rima Tahhan and Dr Ravi Arora received payments for lectures and 
      continuing medical education events as speakers. Dr Salem A. Beshyah, Dr Mahir 
      Jallo and Dr Ravi Arora received reimbursements for travel and accommodation 
      expenses for national and international conferences. Dr Hazem Aly and Dr Sagar 
      Singhal are currently employed as medical advisors by the UAE branch of Novo 
      Nordisk A/S Pharmaceutical Company.
EDAT- 2019/04/17 06:00
MHDA- 2019/06/25 06:00
PMCR- 2018/11/01
CRDT- 2019/04/17 06:00
PHST- 2018/04/23 00:00 [received]
PHST- 2018/07/06 00:00 [revised]
PHST- 2018/07/26 00:00 [accepted]
PHST- 2019/04/17 06:00 [entrez]
PHST- 2019/04/17 06:00 [pubmed]
PHST- 2019/06/25 06:00 [medline]
PHST- 2018/11/01 00:00 [pmc-release]
AID - squmj1811-e447-454 [pii]
AID - 10.18295/squmj.2018.18.04.004 [doi]
PST - ppublish
SO  - Sultan Qaboos Univ Med J. 2018 Nov;18(4):e447-e454. doi: 
      10.18295/squmj.2018.18.04.004. Epub 2019 Mar 28.